1 week ago
Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study.
Positive Data From Inflammatory Bowel Disease Study
Teva and Sanofi SA (NASDAQ:SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.
The study demonstrated durable clinical efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease.
The study involved 130 patients who initially responded to duvakitug in the induction phase, and both doses of duvakitug were well tolerated.
Patients were re-randomized to receive either a 450 mg or 900 mg subcutaneous dose of duvakitug every four weeks for ...
